PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2022 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 8 hours agoPDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2022 Earnings Call Transcript March 28, 2023...
Glyscend Therapeutics Appoints Biotech Industry Veteran Michael Wyzga to its Board of Directors
Benzinga· 8 hours agoGlyscend Therapeutics, a clinical-stage biotechnology company pioneering a new generation of orally administered polymer therapies, today announced the appointment of Michael ...
Benchling Launches Partner Program with Ecosystem of Global Services Partners
Benzinga· 3 hours agoBenchling, the R&D Cloud powering the biotechnology industry, today launched its Benchling Partner Program, bringing a best-in-class, R&D partner ecosystem to biotech ...
3 Biotech Stocks Losing Momentum - Incyte (NASDAQ:INCY), Exelixis (NASDAQ:EXEL)
Benzinga· 1 day agoAs March comes to an end, biotech stocks Exelixis (EXEL), MacroGenics (MGNX), and Puma Biotechnology (PBYI) have been losing momentum. Increasing investments ...
PDS Biotech to Participate in Cantor's Future of Oncology Virtual Symposium - PDS Biotechnology...
Benzinga· 1 day agoFLORHAM PARK, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and
7 Biotech Stocks to Buy for Breakthrough Treatments and Cures - Beam Therapeutics (NASDAQ:BEAM),...
Benzinga· 20 hours agoWhile it’s a common conspiracy theory – and comedic punchline – that medical innovators only seek to manage problems rather than cure them, the reality is that several biotech
Biotech Stock Roundup: VKTX, BMEA, ITCI Soar on Study Data, INCY Faces Setback
Zacks via Yahoo Finance· 1 day agoPerformance Image Source: Zacks Investment Research The Nasdaq Biotechnology Index has gained 0.68%...
Biotechnology and Pharmaceuticals
The Wall Street Transcript· 14 hours ago...Organovo Holdings, Inc. ( NASDAQ:ONVO ), TRACON Pharmaceuticals, Inc. ( NASDAQ:TCON ) Pricing Restrictions, Economic Concerns Weigh on Biotech Sector David Nierengarten Next-Generation Immune-Oncology Drugs Show Early Promise Matt Phipps High Cost of Funds...
Biotech's Bearish Turn In 2023, But Eyeing Bullish Seasonal Trends In IBB
Seeking Alpha· 2 days agoBiotech has not participated in the relative strength of growth stocks so far this year. According...
...These ETFs Let You Maximize Your Exposure To The Biotech Industry’s Performance – Whether...
Benzinga· 6 days agoThe Direxion Daily S&P Biotech Bear 3X Shares LABD, similarly seeks to magnify returns on the performance of the S&P Biotechnology Select Industry...
